Table 2 Description of the patient reported outcome measurements (PROMs) describing the severity of epistaxis (ESS and NOSE-HHT), anxiety (HADS-A), depression (HADS-D), fatigue (PROMIS-Fatigue-8a), and physical and mental functioning (SF-36) of the study population
Patient population | Total (%) |
|---|---|
ESS, mean (SD) | 5 (2.1) |
Mild (1–4) | 188 (33) |
Moderate (4–7) | 266 (47) |
Severe (7–10) | 111 (20) |
NOSE-HHT, mean (SD) | 1.7 (0.8) |
Mild (0–1) | 126 (22) |
Moderate (1.01-2) | 239 (42) |
Severe (> 2) | 200 (36) |
HADS-D, mean (SD) | 6.3 (4) |
Normal (0–7) | 369 (65) |
Borderline abnormal (8–10) | 107 (19) |
Abnormal (11–21) | 89 (16) |
HADS-A, mean (SD) | 8 (4.3) |
Normal (0–7) | 275 (49) |
Borderline abnormal (8–10) | 128 (22) |
Abnormal (11–21) | 162(22) |
PROMIS-Fatigue 8a, mean (SD) | 60 (8.5) |
Normal limits (20–54) | 159 (28) |
Mild (55–60) | 106 (19) |
Moderate (61–70) | 242 (43) |
Severe (71–80) | 58 (10) |
SF-36 | mean (SD) |
General Health | 44.3 (22) |
Physical Function | 60.5 (29) |
Physical Limitations | 40.8 (41.8) |
Emotional Limitations | 50.6 (43.7) |
Energy | 35 (20.7) |
Emotional | 62.3 (20) |
Social | 58 (31) |
Pain | 64 (27) |